Clinical Trials Logo

Clinical Trial Summary

This protocol is a multicenter clinical trial of melatonin for sleep disturbances associated with Alzheimer's disease (AD). Frequent nocturnal awakening is a common behavioral symptom of AD. Nighttime wandering and agitated behavior may result in injuries and sleep disruption for caregivers. Alternatives are sorely needed to the currently available sleep medications that have marginal efficacy and serious side effects. Melatonin is a naturally occurring hormone secreted by the pineal gland. It has soporific effects with oral administration and is well tolerated. It enhances sleep in normal older people. Melatonin also may help sleep disturbances associated with AD; however, this remains to be proven.


Clinical Trial Description

In Alzheimer's disease , sleep disruption is one of the most common behavioral problems, occurring in 45 percent of patients. These nocturnal awakenings and agitation lead to considerable burden for caregivers and frequently lead families to the decision of nursing home placement. The proposed study is a randomized, double blind, parallel group, placebo controlled, clinical trial. Placebo will be compared with two doses of melatonin: a 2.5 mg, slow- release preparation and a 10 mg immediate release preparation. One hundred and fifty community-residing AD patients with disrupted sleep will be recruited. Included subjects will meet NINCDS-ADRDA criteria for probable AD. Prior to study entry, disrupted sleep will be documented by clinical history and by 1 to 2 weeks of recording using wrist activity monitors. The treatment period will last 8 weeks. Rest/activity patterns will be recorded by wrist activity monitors. The primary outcome measure will be the change in nocturnal sleep time from baseline to the end of the treatment phase.

Other outcomes also will be examined, including the time awake after sleep onset, sleep latency, sleep efficiency, daytime agitation, and changes in cognition. The relative effectiveness of high and low dose melatonin will be assessed. Adverse events and side effects will be compared by treatment. This study should provide the data necessary to determine whether melatonin is a safe and effective treatment for disrupted sleep associated with AD. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00000171
Study type Interventional
Source National Institute on Aging (NIA)
Contact
Status Completed
Phase Phase 3

See also
  Status Clinical Trial Phase
Recruiting NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Enrolling by invitation NCT03430648 - Is Tau Protein Linked to Mobility Function? N/A
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT03208491 - AZ@GAME-Eco: Economic Assessment of Serious Games for the Management of Alzheimer's Disease and Related Disorders N/A
Not yet recruiting NCT03654911 - Sustainable Method for Alzheimer's Prediction
Recruiting NCT03671889 - ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease N/A
Recruiting NCT03056495 - Clinical Trial to Determine Tolerable Dosis of Vorinostat in Patients With Mild Alzheimer Disease Phase 1
Recruiting NCT03698695 - A Pharmacodynamics, Safety, and Pharmacokinetics Study of THN201 Versus Donepezil in Healthy Male Volunteers Phase 1
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT03095417 - Improving the Recovery and Outcome Every Day After the ICU N/A
Not yet recruiting NCT03256539 - Napping, Sleep, Cognitive Decline and Risk of Alzheimer's Disease N/A
Not yet recruiting NCT03514875 - Effects of Mitochondrial-targeted Antioxidant on Alzheimer's Disease N/A
Not yet recruiting NCT03116126 - Noradrenergic Add-on Therapy With Guanfacine Phase 3
Recruiting NCT02835716 - Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO N/A
Completed NCT02253732 - Skeletal Muscle as a Mediator of Exercise Induced Effects on Metabolism & Cognitive Function: Role for Myokines & miRNAs N/A
Recruiting NCT02317523 - Alzheimer's Caregiver Coping: Mental and Physical Health N/A
Active, not recruiting NCT02172612 - A Pilot Study to Reduce Inappropriate Anticholinergic Prescribing in the Elderly N/A
Completed NCT03034746 - Impact of Physical Activity on Successful Aging N/A